GLP-1 injection site claims: subcutaneous vs. muscle, fact-checked

What did @my.journey.with.marc actually say?

Mark's central claim is that most GLP-1 users are "injecting their Mounjaro or Wegovy wrong" by hitting muscle instead of fatty tissue, and that this causes absorption to be "faster or uneven," explaining why some weeks feel different than others. He recommends pinching two inches of skin before injecting and suggests the outer thigh or lower belly as the most consistent sites. He frames all of this as coming "straight from the official guidance," while adding a standard disclaimer that it is not medical advice.

To his credit, Mark is not selling anything in this clip, is transparent about his own experience losing weight on tirzepatide, and correctly identifies subcutaneous injection as the intended route. He is also right that leaner individuals face a genuine injection-depth challenge. The problem is what he adds on top of those accurate basics, which is where things get shaky.

Does the science back this up?

Partially. The subcutaneous route is correct, and there is real evidence that intramuscular injection of subcutaneous formulations can alter pharmacokinetics. But the claim that accidental intramuscular injection explains week-to-week symptom variability in real-world GLP-1 users is not well supported by clinical data.

Tirzepatide (Mounjaro) has a half-life of approximately five days, and semaglutide (Wegovy) sits at around seven days. Both are designed to produce slow, sustained absorption from subcutaneous depots, specifically to flatten out peaks and troughs. A 2022 pharmacokinetic review by Bergmann et al. in Diabetes, Obesity and Metabolism confirmed that semaglutide's extended half-life largely buffers against minor injection-site variation. The idea that a single slightly-deeper injection would noticeably spike or blunt efficacy that week runs against what these long half-lives are specifically engineered to prevent. Week-to-week variability in hunger, energy, or side effects is far more likely explained by dose escalation, dietary changes, sleep, or stress than by injection depth in most users.

What did they get wrong (or right)?

Mark gets the foundational point right: subcutaneous, not intramuscular, is the correct route for tirzepatide and semaglutide. That is confirmed by the prescribing information for both drugs. The two-finger pinch technique is a reasonable practical tip for leaner individuals, though official guidance from Eli Lilly and Novo Nordisk specifies a 45-degree angle for thinner skin areas rather than a specific pinch distance.

Where he goes wrong is the causal chain. Saying it "can be faster or uneven" and then connecting that to week-to-week cravings or energy shifts is a leap the pharmacokinetic data does not really support for these specific molecules. Their long half-lives exist precisely to prevent that kind of acute variability. He also conflates GLP-1 receptor agonists (Mounjaro, Wegovy) with the peptides category this video is tagged under, which includes research-use peptides like BPC-157 or CJC-1295. Those are entirely different compounds with different pharmacokinetic profiles and regulatory statuses. The injection-depth logic does not transfer uniformly across that category.

What should you actually know?

If you are injecting Mounjaro or Wegovy at home, subcutaneous injection into the abdomen, outer thigh, or upper arm is correct and supported by the prescribing information. Rotating sites matters for tissue health and lipohypertrophy prevention, which is a real and underappreciated issue. A 2019 study by Blanco et al. in Diabetes Technology and Therapeutics found lipohypertrophy at injection sites was associated with more variable glucose control in insulin users, and the principle applies broadly to subcutaneous biologics.

But if your Mounjaro weeks feel different from each other, injection technique is probably not the main culprit. Talk to your prescriber about dose escalation schedules, meal composition, sleep quality, and activity levels before troubleshooting your injection angle. Symptom variability on GLP-1 medications is common, documented, and usually explained by factors that have nothing to do with whether you pinched two inches of skin.

• Always use the correct needle length for your body composition. Your prescribing pharmacist or clinician can advise on this.
• Rotate injection sites systematically to avoid lipohypertrophy.
• If you consistently notice injection-site pain or lumps, raise it with your prescriber, not a TikTok comment section.